Michael B. Atkins
Georgetown University Medical Center
CancerPathologyImmunologyRenal cell carcinomaMedicine
What is this?
Publications 137
#1Ziad Bakouny (Harvard University)H-Index: 5
#2David A. Braun (Harvard University)H-Index: 6
Last. Meng Xiao He (Harvard University)H-Index: 3
view all 52 authors...
Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are particularly effective for these tumors1−3, although the biological basis for this property is largely unknown. Here, we evaluate multiple clinical trial and real-world cohorts of S/R RCC to characterize their molecular features, clinical outcomes, and immunologic characteristics. We find tha...
#1Toni K. Choueiri (Brigham and Women's Hospital)H-Index: 81
#2Robert J. Motzer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 100
Last. Hyuk-JoonLee (UOU: University of Ulsan)H-Index: 188
view all 25 authors...
ABSTRACT Background The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib vs sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis. Patients and methods Treatment-naive patients with aRCC were randomized (1:1) to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orall...
1 CitationsSource
#1Wenxin Xu (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 4
#2Michael B. Atkins (MedStar Georgetown University Hospital)H-Index: 40
Last. David F. McDermott (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 73
view all 3 authors...
Kidney cancer has unique features that make this malignancy attractive for therapeutic approaches that target components of the immune system. Immune checkpoint inhibition is a well-established part of kidney cancer treatment, and rapid advances continue to be made in this field. Initial preclinical studies that elucidated the biology of the programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) immune checkpoints led to a series of...
2 CitationsSource
#1Isabella Claudia Glitza (University of Texas MD Anderson Cancer Center)H-Index: 14
#2Keiran S.M. SmalleyH-Index: 33
Last. Peter A. ForsythH-Index: 54
view all 18 authors...
In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical...
1 CitationsSource
#1Darren Mays (GUMC: Georgetown University Medical Center)H-Index: 20
#2Jaeil Ahn (GUMC: Georgetown University Medical Center)H-Index: 3
Last. Kenneth P. Tercyak (GUMC: Georgetown University Medical Center)H-Index: 34
view all 6 authors...
#1Neil J. Shah (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Ghassan Al-Shbool (MedStar Washington Hospital Center)H-Index: 1
Last. Chul Kim (MedStar Georgetown University Hospital)H-Index: 1
view all 11 authors...
Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI therapy in patients with both cancer and chronic viral infections is not well established as most clinical trials of ICIs excluded these patient populations. We performed a retrospective analysis of patients with advanced-stage cancers and HIV, HBV, or HCV infection treated with ICI therapy at...
3 CitationsSource
#1Wenxin Xu (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 4
#2Maneka Puligandla (Harvard University)H-Index: 7
Last. Rupal S. Bhatt (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 20
view all 13 authors...
Purpose: The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial. Experimental Design: Patients with resected high-risk RCC were randomized to sunitinib, sorafenib, or placebo. Plasma from 413 patients was analyzed from post-nephrectomy baseline, 4 weeks, and 6 weeks after treatment initiation. Mixed effects and Cox proportional hazards m...
#1Dana Alsaadi (MedStar Georgetown University Hospital)H-Index: 2
#2Neil J. Shah (MedStar Georgetown University Hospital)H-Index: 1
Last. Michael B. Atkins (MedStar Georgetown University Hospital)H-Index: 40
view all 4 authors...
Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also being recognized. Here we report a case of ICI-induced celiac disease. A 74-year-old Caucasian female with metastatic renal carcinoma received second line nivolumab (anti-PD1 antibody) after initial disease progressi...
#1Shannon M. White (GUMC: Georgetown University Medical Center)H-Index: 3
#2Maria Laura Avantaggiati (GUMC: Georgetown University Medical Center)H-Index: 31
Last. Chunling Yi (GUMC: Georgetown University Medical Center)H-Index: 11
view all 11 authors...
Summary Merlin/NF2 is a bona fide tumor suppressor whose mutations underlie inherited tumor syndrome neurofibromatosis type 2 (NF2), as well as various sporadic cancers including kidney cancer. Multiple Merlin/NF2 effector pathways including the Hippo-YAP/TAZ pathway have been identified. However, the molecular mechanisms underpinning the growth and survival of NF2-mutant tumors remain poorly understood. Using an inducible orthotopic kidney tumor model, we demonstrate that YAP/TAZ silencing is s...
2 CitationsSource
#1Suthee Rapisuwon (GUMC: Georgetown University Medical Center)H-Index: 1
#2Benjamin Izar (Harvard University)H-Index: 15
Last. Michael B. Atkins (GUMC: Georgetown University Medical Center)H-Index: 40
view all 12 authors...
Balancing the potential for durable remissions with autoimmune-like toxicities is a key clinical challenge in the use of immune checkpoint inhibitors (ICI). Certain toxicities are associated with an increased response rate; however, the molecular underpinnings of this association are poorly understood. Here, we report a patient with wide spread uveal melanoma who had an exceptional response to treatment with ipilimumab and nivolumab, but suffered severe immune-related sequelae, including central...
2 CitationsSource